Inmune Shares Owned by Insiders

INMB
 Stock
  

USD 6.91  0.79  10.26%   

Inmune Bio fundamentals help investors to digest information that contributes to Inmune Bio's financial success or failures. It also enables traders to predict the movement of Inmune Stock. The fundamental analysis module provides a way to measure Inmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inmune Bio stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Inmune Shares Owned by Insiders Analysis

Inmune Bio's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Insiders Shares 
 = 
Executives Shares 
Employees 
More About Shares Owned by Insiders | All Equity Analysis

Current Inmune Bio Shares Owned by Insiders

    
  35.06 %  
Most of Inmune Bio's fundamental indicators, such as Shares Owned by Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Compare to competition

Based on the latest financial disclosure, 35.06% of Inmune Bio are shares owned by insiders. This is 130.96% higher than that of the Healthcare sector and 147.25% higher than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.

Inmune Shares Owned by Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inmune Bio's direct or indirect competition against its Shares Owned by Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inmune Bio could also be used in its relative valuation, which is a method of valuing Inmune Bio by comparing valuation metrics of similar companies.
Inmune Bio is currently under evaluation in shares owned by insiders category among related companies.

Inmune Bio Institutional Holders

Institutional Holdings refers to the ownership stake in Inmune Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inmune Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inmune Bio's value.
Security TypeSharesValue
Vanguard Group IncCommon Shares553.6 K4.9 M
Blackrock IncCommon Shares234.1 K2.1 M
Morgan StanleyCommon Shares208.3 K1.8 M
Janney Montgomery Scott LlcCommon Shares211.3 K1.7 M
Act Capital Management LlcCommon Shares160.5 K1.4 M
Geode Capital Management LlcCommon Shares138.2 K1.2 M
Deutsche Bank AgCommon Shares121 K1.1 M
Group One Trading LpPut Options45 K398 K
Susquehanna International Group LlpCall Options26.5 K234 K

Inmune Fundamentals

About Inmune Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inmune Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Inmune Bio Piotroski F Score and Inmune Bio Altman Z Score analysis. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.